Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
The new fluoroquinolone trovafloxacin was tested against a ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus strain in the rabbit model of endocarditis. Trovafloxacin was more effective than vancomycin (CFU/g of vegetation, 2.65 +/- 1.87 versus 4.54 +/- 2.80 [mean +/- standard deviation]; P < 0.05) or ampicillin-sulbactam plus rifampin (4.9 +/- 1.1 CFU/g). The addition of ampicillin-sulbactam to trovafloxacin tended to reduce titers further.
Kim
Y S
YS
Infectious Diseases Laboratory, San Francisco General Hospital, and Departments of Medicine and Neurology, University of California, San Francisco, San Francisco, California 94143-0811, USA.
Liu
Q
Q
Chow
L L
LL
Chambers
H F
HF
Täuber
M G
MG
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D024841:Fluoroquinolones; D006321:Heart / Q000382:microbiology; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology*; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D002939:Ciprofloxacin; C080163:trovafloxacin